vs
Aligos Therapeutics, Inc.（ALGS）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是Aligos Therapeutics, Inc.的2673.2倍（$451.8M vs $169.0K）。HALOZYME THERAPEUTICS, INC.净利率更高（-31.3% vs -11763.9%，领先11732.6%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs -72.1%）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs -50.7%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
ALGS vs HALO — 直观对比
营收规模更大
HALO
是对方的2673.2倍
$169.0K
营收增速更快
HALO
高出123.7%
-72.1%
净利率更高
HALO
高出11732.6%
-11763.9%
两年增速更快
HALO
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $451.8M |
| 净利润 | $-19.9M | $-141.6M |
| 毛利率 | — | 82.6% |
| 营业利润率 | -12907.7% | -20.6% |
| 净利率 | -11763.9% | -31.3% |
| 营收同比 | -72.1% | 51.6% |
| 净利润同比 | 75.8% | -203.3% |
| 每股收益（稀释后） | $4.23 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGSHALO
| Q4 25 | $169.0K | $451.8M | ||
| Q3 25 | $741.0K | $354.3M | ||
| Q2 25 | $965.0K | $325.7M | ||
| Q1 25 | $311.0K | $264.9M | ||
| Q4 24 | $606.0K | $298.0M | ||
| Q3 24 | $1.3M | $290.1M | ||
| Q2 24 | $1.1M | $231.4M | ||
| Q1 24 | $694.0K | $195.9M |
净利润ALGSHALO
| Q4 25 | $-19.9M | $-141.6M | ||
| Q3 25 | $-31.5M | $175.2M | ||
| Q2 25 | $-15.9M | $165.2M | ||
| Q1 25 | $43.1M | $118.1M | ||
| Q4 24 | $-82.2M | $137.0M | ||
| Q3 24 | $-19.3M | $137.0M | ||
| Q2 24 | $5.1M | $93.2M | ||
| Q1 24 | $-34.9M | $76.8M |
毛利率ALGSHALO
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率ALGSHALO
| Q4 25 | -12907.7% | -20.6% | ||
| Q3 25 | -3827.4% | 61.5% | ||
| Q2 25 | -1924.0% | 62.2% | ||
| Q1 25 | -6187.5% | 53.4% | ||
| Q4 24 | -3393.2% | 58.9% | ||
| Q3 24 | -1610.5% | 56.3% | ||
| Q2 24 | -2489.5% | 50.7% | ||
| Q1 24 | -3176.7% | 48.8% |
净利率ALGSHALO
| Q4 25 | -11763.9% | -31.3% | ||
| Q3 25 | -4256.0% | 49.5% | ||
| Q2 25 | -1643.8% | 50.7% | ||
| Q1 25 | 13854.7% | 44.6% | ||
| Q4 24 | -13556.1% | 46.0% | ||
| Q3 24 | -1540.7% | 47.2% | ||
| Q2 24 | 477.0% | 40.3% | ||
| Q1 24 | -5023.5% | 39.2% |
每股收益（稀释后）ALGSHALO
| Q4 25 | $4.23 | $-1.13 | ||
| Q3 25 | $-3.04 | $1.43 | ||
| Q2 25 | $-1.53 | $1.33 | ||
| Q1 25 | $-2.11 | $0.93 | ||
| Q4 24 | $-13.10 | $1.06 | ||
| Q3 24 | $-3.07 | $1.05 | ||
| Q2 24 | $0.81 | $0.72 | ||
| Q1 24 | $-5.58 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $133.8M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $53.5M | $48.8M |
| 总资产 | $88.5M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资ALGSHALO
| Q4 25 | $77.8M | $133.8M | ||
| Q3 25 | $99.1M | $419.7M | ||
| Q2 25 | $122.9M | $61.9M | ||
| Q1 25 | $137.9M | $176.3M | ||
| Q4 24 | $56.9M | $115.8M | ||
| Q3 24 | $74.9M | $154.3M | ||
| Q2 24 | $94.5M | $187.9M | ||
| Q1 24 | $112.7M | $164.6M |
总债务ALGSHALO
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益ALGSHALO
| Q4 25 | $53.5M | $48.8M | ||
| Q3 25 | $71.8M | $503.9M | ||
| Q2 25 | $101.9M | $332.7M | ||
| Q1 25 | $116.4M | $482.3M | ||
| Q4 24 | $-29.0M | $363.8M | ||
| Q3 24 | $50.1M | $452.7M | ||
| Q2 24 | $67.2M | $289.4M | ||
| Q1 24 | $59.8M | $177.8M |
总资产ALGSHALO
| Q4 25 | $88.5M | $2.5B | ||
| Q3 25 | $109.8M | $2.2B | ||
| Q2 25 | $134.7M | $2.1B | ||
| Q1 25 | $150.7M | $2.2B | ||
| Q4 24 | $70.1M | $2.1B | ||
| Q3 24 | $88.4M | $2.1B | ||
| Q2 24 | $108.8M | $2.0B | ||
| Q1 24 | $127.9M | $1.8B |
负债/权益比ALGSHALO
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.7M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | — | $217.6M |
| 自由现金流率自由现金流/营收 | — | 48.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $644.6M |
8季度趋势，按日历期对齐
经营现金流ALGSHALO
| Q4 25 | $-21.7M | $219.0M | ||
| Q3 25 | $-24.3M | $178.6M | ||
| Q2 25 | $-15.5M | $99.7M | ||
| Q1 25 | $-20.9M | $154.2M | ||
| Q4 24 | $-18.4M | $178.5M | ||
| Q3 24 | $-20.1M | $115.4M | ||
| Q2 24 | $-19.5M | $55.8M | ||
| Q1 24 | $-22.7M | $129.4M |
自由现金流ALGSHALO
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $125.9M |
自由现金流率ALGSHALO
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 64.3% |
资本支出强度ALGSHALO
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
现金转化率ALGSHALO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | -0.49× | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | -3.85× | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGS
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
